费里丁与脂质体:基于蛋白质和脂质的药物输送系统的比较分析
Yang Liu1, Feiyan Zhu1, Jiuyang He1
1Experimental Center of Advanced Materials, School of Materials Science & Engineering, Beijing Institute of Technology, Beijing 100081, China.
Bioconjugate chemistry
|February 10, 2025
概括
作为先进的药物输送系统 (DDS),费里丁纳米显示出有前途的前景,与已建立的脂质体相比,提供优越的瘤向性和生物相容性,用于增强癌症治疗.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 瘤学 治疗学 治疗学
背景情况:
- 药物递送系统 (DDS) 对于有针对性的治疗剂递送至关重要,提高了稳定性和特异性.
- 自20世纪90年代以来,FDA批准的纳米药物脂质体是广泛使用的DDS,但面临着精确准的挑战.
- 费里丁是一种天然蛋白质纳米,是一种具有创新性的DDS,具有固有的瘤向和生物相容性优势.
研究的目的:
- 为了全面分析费里和脂质体作为药物输送载体.
- 为了比较它们的药物载荷能力,瘤向能力和生物相容性.
- 评估它们的治疗潜力和适合临床转化.
主要方法:
- 作为DDSs的费里和脂质体的比较分析.
- 对封装效率和生物相容性的评估.
- 评估瘤向能力和治疗潜力.
主要成果:
- 脂质体和费里都表现出极好的封装效率和生物相容性.
- 费里丁具有固有的瘤向能力,精确度超过脂质体.
- 脂质体在精确准方面面临着尚未解决的挑战,而费里丁在临床环境中仍然在很大程度上未被探索.
结论:
- 费里丁是一种有前途的药物输送载体,用于瘤向治疗.
- 费里丁固有的优势使其成为未来临床翻译的强有力的候选者.
- 进一步研究基于费里的DDS可以克服当前纳米药物的局限性.
更多相关视频
00:11Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins
Published on: August 31, 2019
23.6K
08:44Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes
Published on: July 30, 2020
4.2K
相关概念视频
Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
